This article was originally published in English
New results from a clinical trial evaluating the drug show positive results in reducing the risk of heart failure.
ADVERTISING
The slimming drug Tirzepatide reduced the risk of hospitalization by 38% or death in obese adults with heart failure, compared with a placebo, according to Eli Lilly.
The American pharmaceutical company gave to announce the results of a phase 3 clinical trial of the drug in obese adults with a common type of heart failure.
The drug is marketed under the name Zepbound for weight loss and Mounjaro for diabetes. The use of Mounjaro was approved in the European Union in 2022.
Tirzepatide also improved symptoms of heart failure and physical limitations, the company said, and helped adults lose 15.7% of their body weight compared with only 2.2% for those taking a placebo.
They will continue to evaluate the results of the trial
The company stated that would continue to evaluate the results of the trial and would introduce them to the regulatory agencies later this year.
The trial included 731 participants from nine countries that received 5, 10 or 15 milligrams of Tirzepatide, depending on their tolerance, or a placebo. The drug was administered once a week.
What is Tirzepatide?
La Tirzepatida It is one of the most popular anti-obesity drugs. and type 2 diabetes, in the same class as semaglutide, the active ingredient in drugs Ozempic and Wegovy from Novo Nordisk.
Tirzepatide also mimics the hormone GIP (glucose-dependent insulinotropic polypeptide), which regulates blood glucose levels.
Semaglutide has been shown to reduces cardiovascular episodes such as stroke, myocardial infarction and death in adults with pre-existing conditions.
The European Medicines Agency Last week approved a positive opinion on the Expanding the use of Wegovy to include prevention of serious cardiovascular problems in overweight adults with cardiovascular disease.
Los adverse side effects The most common adverse reactions of tirzepatide were diarrhea, nausea, constipation and vomitingaccording to Eli Lilly, although the drug can also cause more serious side effects.
Help people with obstructive sleep apnea
A recent study published in the ‘New England Journal of Medicine’ revealed that Tirzepatide also can help people suffering from obstructive sleep apneaa serious sleep disorder in which people stop breathing while sleeping.
However, the company noted that the production of the drug involves risks and uncertainties and there is no guarantee that it will be approved for patients with heart failure.
Cost, a major barrier for patients
Experts have also warned that Cost and access remain barriers for the use of these best-selling weight loss drugs, which are in short supply due to their popularity.
Weight problems and obesity are increasing in EU states, with an estimated 1.5 million people in the world. 52.7% of the EU adult population is overweight in 2019, according to the bloc’s statistical office, Eurostat.
